UT-MD Anderson Cancer Center: Neoadjuvant Immunotherapy With Relatlimab And Nivolumab Is Safe And Effective In Stage III Melanoma
October 27, 2022
October 27, 2022
HOUSTON, Texas, Oct. 27 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Oct. 26, 2022:
* * *
Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer
* * *
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of . . .
* * *
Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer
* * *
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of . . .